Business Context and Reporting Period
Autonomix Medical, Inc. (AMIX), a Delaware corporation and emerging growth company, filed this Form 8-K on November 22, 2024, to report the entry into a material definitive agreement. The filing details a firm commitment underwritten public offering that closed on November 25, 2024.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10.0 million (including partial over-allotment exercise).
- Securities Issued:
- 458,691 Common Units (1 Common Stock share + 1 Series A Warrant) at $6.540 per unit.
- 917,596 Pre-Funded Units (1 Pre-Funded Warrant + 1 Series A Warrant) at $6.539 per unit.
- 156,809 additional shares and warrants issued via partial over-allotment exercise.
- Underwriting Costs: 8.0% discount on the public offering price plus reimbursement of out-of-pocket expenses up to $115,000.
- Representative's Warrants: 91,985 warrants issued to the underwriter representative.
- Warrant Terms: Series A Warrants have an exercise price of $6.540 and a 5-year term. Pre-Funded Warrants have an exercise price of $0.001 and are immediately exercisable.
Material Changes and Use of Proceeds
This transaction represents a significant capital raise for the Company. The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a current report regarding a specific transaction rather than a periodic financial statement. The Company intends to use the net proceeds to fund clinical trials, research and development, intellectual property development, and working capital.
Outlook, Risks, and Management Commentary
Management has indicated that the capital raised will support ongoing clinical and R&D activities. The filing notes that the Underwriting Agreement contains customary representations, warranties, and indemnification obligations. Investors are cautioned that the representations in the agreement are for risk allocation between parties and may not reflect materiality standards viewed by stockholders. The filing incorporates by reference press releases issued on November 22 and November 25, 2024, regarding the pricing and closing of the offering.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting the 8.0% underwriting discount and estimated expenses.
- Confirm the dilution impact of the 1,376,287 total units sold plus the 156,809 over-allotment shares and 91,985 representative warrants.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Warrant Agency Agreement (Exhibit 4.3) for specific covenants and exercise conditions.
- Monitor the Company's cash burn rate relative to the $10.0 million raised to assess runway for clinical trials.